OKYO Pharma Limited (OKYO)
OKYONASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$1.35
0.0000 (0.00%) today
At the close, Nov 13, 4:00 PM ET. Pre-market $1.31 -2.96%
- Market cap
- $68.75m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.26 to $3.20
- Average volume
- –
- Previous close
- $1.35
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $6.00, +344.4% from here
Earnings
next estimate $-0.0300Next report
Financials
No quarterly figures from the source.
News
8 latest- OKYO Pharma Begins Phase 3 Trial Of Urcosimod For Neuropathic Corneal Pain RTTNews · Oct 6, 2026
- OKYO Pharma Gains FDA Alignment To Advance Urcosimod RTTNews · Jul 8, 2026
- OKYO Pharma Says FDA Supports Advancement Of NEPTUNE Clinical Trial For Urcosimod RTTNews · Jul 8, 2026
- What Makes OKYO Pharma (OKYO) a New Buy StockZacks · May 20, 2026
- OKYO Pharma (OKYO) Price Target Increased by 25.00% to 10.20Fintel · May 13, 2026
- Piper Sandler Initiates Coverage of OKYO Pharma (OKYO) with Overweight RecommendationFintel · Feb 20, 2026
- OKYO Pharma Prices $20 Mln Share Offering At $1.85/shr; Stock Down RTTNews · Feb 13, 2026
- Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE RTTNews · Jan 30, 2026
The company
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. Lead candidate, urcosimod for neuropathic corneal pain (NCP), recently announced first patients enrolled in Phase 3 NEPTUNE trial.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- Europe
- Website
- okyopharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.